Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study.
ATN biomarkers
Alzheimer's disease
cognition
imaging
memory
plasma markers
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
16
11
2023
received:
29
06
2023
accepted:
04
12
2023
medline:
18
3
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
ppublish
Résumé
Identification of Alzheimer's disease (AD) needs inexpensive, noninvasive biomarkers, with validation in all populations. We collected plasma markers in older American Indian individuals: phosphorylated-tau181 (pTau181); amyloid-beta (Aβ) 40,42; glial fibrillary acidic protein (GFAP); and neurofilament light chain (NfL). Plasma markers were analyzed for discriminant properties with cognitive status and etiology using receiver operating characteristic (ROC) analysis. PTau181, GFAP, NfL plasma values were significantly associated with cognition, but Aβ were not. Discriminant performance was moderate for individual markers, with pTau181, GFAP, NfL performing best, but an empirically selected panel of markers (age, sex, education, pTau181, GFAP, NfL, Aβ4240 ratio) had excellent discriminant performance (AUC > 0.8). In American Indian individuals, pTau181 and Aβ values suggested more common pathology than in majority populations. Aβ was less informative than in other populations; however, all four markers were needed for a best-performing dementia diagnostic model. These data validate utility of AD plasma markers, while suggesting population-specific diagnostic characteristics.
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2072-2079Subventions
Organisme : NHLBI NIH HHS
ID : 75N92019D00029
Pays : United States
Organisme : NIH HHS
ID : K01AG057821
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92019D00027
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066509
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92019D00030
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92019D00028
Pays : United States
Organisme : NIH HHS
ID : P50AG005136
Pays : United States
Organisme : NIH HHS
ID : R01HL093086
Pays : United States
Organisme : NIH HHS
ID : R01HL093086
Pays : United States
Organisme : NIH HHS
ID : P50AG005136
Pays : United States
Organisme : NIH HHS
ID : K01AG057821
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92019D00027
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92019D00028
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92019D00029
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92019D00030
Pays : United States
Informations de copyright
© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ. Biomarkers for the early detection and progression of Alzheimer's disease. Neurotherapeutics. 2017;14(1):35-53. doi:10.1007/s13311-016-0481-z
Tsvetkova DZ, Bergquist SH, Parker MW, et al. Fear and uncertainty do not influence reported willingness to undergo lumbar punctures in a U.S. Multi-cultural cohort. Front Aging Neurosci. 2017;9:22. doi:10.3389/fnagi.2017.00022
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684. doi:10.1016/S1474-4422(16)00070-3
Suchy-Dicey AM, Shibata D, Best LG, et al. Cranial magnetic resonance imaging in elderly American Indians: design, methods, and implementation of the cerebrovascular disease and its consequences in American Indians study. Neuroepidemiology. 2016;47(2):67-75. doi:10.1159/000443277
Suchy-Dicey AM, Oziel K, Sawyer C, et al. Educational and clinical associations with longitudinal cognitive function and brain imaging in American Indians: the strong heart study. Neurology. 2022;99(24):e2637-e2647. doi:10.1212/WNL.0000000000201261
Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484-1497. doi:10.1002/alz.12510
Cullen NC, Janelidze S, Mattsson-Carlgren N, et al. Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimers Dement. 2022. Epub ahead of print. PMID: 35699240; PMCID: PMC9747985. doi:10.1002/alz.12706
Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433. doi:10.1016/S1474-4422(20)30071-5
Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test (CVLT-II). 2nd ed. Adult Version. The Psychological Corporation; 2000.
Teng EL, Chang Chui H. The Modified Mini-Mental (3MS) Examination. Journal Clinical Psychiatry. 1987;48(8):314-318.
Benton AL, Hansher K. Multilingual Aphasia Examination. 2nd ed. AJA Associates; 1976.
Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210-216. doi:10.1097/01.wad.0000213865.09806.92
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x
Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. Neuropsychologia. 2011;49(1):43-48. doi:10.1016/j.neuropsychologia.2010.10.026
Llinas-Regla J, Vilalta-Franch J, Lopez-Pousa S, Calvo-Perxas L, Torrents Rodas D, Garre-Olmo J. The trail making test. Assessment. 2017;24(2):183-196. doi:10.1177/1073191115602552
Liew TM. Developing a brief neuropsychological battery for early diagnosis of cognitive impairment. J Am Med Dir Assoc. 2019;20(8):1054 e11-1054 e20. doi:10.1016/j.jamda.2019.02.028
Ivanova I, Salmon DP, Gollan TH. The multilingual naming test in Alzheimer's disease: clues to the origin of naming impairments. J Int Neuropsychol Soc. 2013;19(3):272-283. doi:10.1017/S1355617712001282
North KE, Goring HH, Cole SA, et al. Linkage analysis of LDL cholesterol in American Indian populations: the Strong Heart Family Study. J Lipid Res. 2006;47(1):59-66. doi:10.1194/jlr.M500395-JLR200
Kataoka S, Robbins DC, Cowan LD, et al. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 1996;16(8):918-925.
Rothberg MB, Kehoe ED, Courtemanche AL, et al. Recognition and management of chronic kidney disease in an elderly ambulatory population. J Gen Intern Med. 2008;23(8):1125-1130. doi:10.1007/s11606-008-0607-z
Tsiknia AA, Edland SD, Sundermann EE, et al. Sex differences in plasma p-Tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression. Mol Psychiatry. 2022;27(10):4314-4322. doi:10.1038/s41380-022-01675-8
Windon C, Iaccarino L, Mundada N, et al. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimers Dement. 2022;14(1):e12315. doi:10.1002/dad2.12315
Gu L, Guo Z. Alzheimer's Abeta42 and Abeta40 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126(3):305-311. doi:10.1111/jnc.12202
Chatterjee P, Pedrini S, Stoops E, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Transl Psychiatry. 2021;11(1):27. doi:10.1038/s41398-020-01137-1
Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer's disease. Brain. 2021;144(11):3505-3516. doi:10.1093/brain/awab223
Mielke MM, Syrjanen JA, Blennow K, et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):e252-e260. doi:10.1212/WNL.0000000000007767
Simren J, Andreasson U, Gobom J, et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. Brain Commun. 2022;4(4):fcac174. doi:10.1093/braincomms/fcac174
Harp C, Thanei GA, Jia X, et al. Development of an age-adjusted model for blood neurofilament light chain. Ann Clin Transl Neurol. 2022;9(4):444-453. doi:10.1002/acn3.51524
Benedet AL, Brum WS, Hansson O, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14(1):26. doi:10.1186/s13195-021-00942-0
Coomans EM, Verberk IMW, Ossenkoppele R, et al. A head-to-head comparison between plasma pTau181 and tau PET Along the Alzheimer's disease continuum. J Nucl Med. 2023;64(3):437-443. doi:10.2967/jnumed.122.264279
Benussi A, Cantoni V, Rivolta J, et al. Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration. Alzheimers Res Ther. 2022;14(1):155. doi:10.1186/s13195-022-01094-5
Suchy-Dicey A, Howard B, Longstreth WT Jr, Reiman EM, Buchwald D. APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: data from the Strong Heart Study. Alzheimers Dement. 2022;18(12):2518-2526. doi:10.1002/alz.12573
Suchy-Dicey AM, Muller CJ, Madhyastha TM, et al. Telomere length and magnetic resonance imaging findings of vascular brain injury and Central Brain Atrophy: the Strong Heart Study. Am J Epidemiol. 2018;187(6):1231-1239. doi:10.1093/aje/kwx368